Immunotherapy after surgery reduces the risk of fatal relapse in advanced bladder cancer

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Cancer cell during cell division. Credit: National Institutes of Health

A Phase 3 clinical trial led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients at high risk for the cancer to return. deadly metastatic. results published in The New England Journal of Medicine. Nivolumab immunotherapy was used as adjunctive therapy, which is administered after surgery in the hope of maximizing its effectiveness.

The randomized trial, called “Checkmate 274,” showed that using nivolumab increased the chances of these patients staying cancer-free after surgery compared to patients receiving a placebo. The mean time before relapse almost doubled in patients who received nivolumab, which is a monoclonal antibody immune checkpoint inhibitor that harnesses the immune system to fight cancer.

Surgery that removes the bladder or kidney and ureter is currently the standard of care for patients with urothelial cancer who have entered the muscle or , although half of these patients later relapse with lethal metastatic cancer. Unfortunately for these patients, no consensus has emerged on post-surgery treatments that may reduce the risk of cancer recurrence.

“These results of the clinical trial promise to impact the standard treatment of patients with urothelial cancer of the kidney, ureter, or bladder, reducing the risk of metastatic recurrence after surgery,” said Matthew Galsky, MD, lead author of the study and director of Genitourinary Medical Oncology, co-director of the Center of Excellence against Bladder Cancer, associate director of translational research and co-director of the clinical research program on cancer at the Tisch Cancer Institute of the Faculty of Medicine Icahn of Mount Sinai. “Almost 200,000 people die every year all over the world, so advances like immunotherapy that are used in this way bring hope. ”

Immunotherapy treatment after chemotherapy significantly slows metastatic bladder cancer

Citation: Immunotherapy after Surgery Reduces Risk of Deadly Relapse in Advanced Bladder Cancer (2021, June 2) Retrieved June 2, 2021 at -deadly-relapse-advanced.html

This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link



Recent Posts

Cisco Duo wins Best in KLAS again for the second year in a row
Co-author of Allison Norfleet The results of the Best in KLAS Awards 2024: Software and Services the...
Read More
Enhance your Cisco HIMSS24 experience
The Cisco Customer Experience Healthcare Practice helps customers leverage the use of Cisco technology...
Read More
HIMSS 2024 Find out before you go
The future of healthcare is coming into focus! Now more than ever, we believe that technology is a critical...
Read More

Related Posts